RETA Reata Pharma: Year-over-year earnings per share growth for the last twelve months

Official company branding of Reata Pharmaceuticals, Inc. (RETA)

Insurance bureaucracy and the launch costs of Skyclarys are putting pressure on revenues for Reata Pharmaceuticals (RETA). The quarterly EPS growth trend clearly demonstrates the actual profitability per share, where the parameter value equals 0.00. A monopoly status in the treatment of Friedreich's ataxia provides Reata Pharmaceuticals (RETA) with pricing power, while the implementation of ESG standards in laboratories minimizes harmful emissions.

Reata Pharmaceuticals, Inc. (RETA) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 10/07/2023

Analytical breakdowns for Reata Pharmaceuticals

- share price and consensus valuation forecast:
Fundamental company analysis:reatapharma.com, RETA
Manufactured product of Reata Pharma

This indicator measures the quarterly dynamics of earnings per share, allowing for an assessment of whether operational efficiency is outpacing cost inflation and rising expenses. By analyzing the current level of quarterly EPS growth, an investor can see Reata Pharmaceuticals (RETA) exercising unrestricted pricing power as a monopolist in Friedreich's ataxia therapy, which converts directly into exceptional business margins.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Rapport Corp - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Therapeutics|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Larimar Pharma LRMR|Year-over-year net earnings per share growth for the last 12 months CAPR|Earnings per share growth in annualized terms for the last twelve months Entrada TRDA|Quarterly EPS earnings growth PTHS|Year-over-year net earnings per share growth for the last 12 months MediciNova MNOV|Year-over-year earnings per share growth for the last twelve months Serina Therapeutics SER|Year-over-year net earnings per share change for the last twelve months BioXcel Therapeutics Inc (BTAI)|PMN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Apimeds Pharmaceuticals US APUS|AEON Biopharma (AEON) - Year-over-year earnings per share growth for the last twelve months|NLS Pharma - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Bionomics Ltd.|FSD Pharma - Year-over-year net earnings per share trend for the last twelve months